Product image of Mifomet (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Mifomet

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Mifomet (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride and Sitagliptin, the active ingredient in Mifomet, is a Biguanide/DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to control blood glucose levels.

GNH India supplies Mifomet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Customers benefit from reliable logistics, comprehensive documentation, and responsive technical support throughout the procurement process.

Manufacturer / TM Owner

Bausch Health Ireland Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mifomet combines two antidiabetic agents that act on glucose metabolism and insulin secretion.

  • Type 2 diabetes mellitus: improves glycaemic control when added to diet, exercise and other oral agents.
  • Inadequate control with metformin alone: provides additional glucose‑lowering effect through DPP‑4 inhibition.
  • Combination therapy in patients requiring both insulin sensitisation and enhanced incretin activity: simplifies regimen by delivering two mechanisms in one tablet.

How It Works

  • Metformin reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity, while Sitagliptin blocks the enzyme dipeptidyl peptidase‑4, raising endogenous incretin levels and promoting glucose‑dependent insulin secretion. Together they lower fasting and post‑prandial blood glucose without causing direct insulin release.

Side Effects

Adverse reactions may occur with any antidiabetic therapy and should be monitored.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhoea: loose stools, usually transient.
  • Abdominal discomfort: cramping or pain.
  • Headache: mild tension‑type.
  • Hypoglycaemia (when combined with sulfonylureas or insulin): sweating, shakiness.
  • Metallic taste: transient oral sensation.

Serious or Rare Side Effects

  • Lactic acidosis: severe metabolic disturbance, medical emergency.
  • Pancreatitis: abdominal pain with elevated enzymes.
  • Severe allergic reactions: rash, angioedema, anaphylaxis.
  • Hepatic dysfunction: jaundice, elevated liver enzymes.
  • Persistent hypoglycaemia: confusion, loss of consciousness.
  • Renal impairment worsening: accumulation of metformin.

Precautions & Warnings

Patients should be evaluated for contraindications and monitored during therapy.

  • Renal function assessment: avoid in severe renal impairment.
  • Hepatic disease monitoring: use cautiously in liver dysfunction.
  • Cardiovascular status: monitor for heart failure exacerbation.
  • Concomitant medications: review for drugs affecting glucose or renal clearance.
  • Pregnancy and lactation: discuss risks with healthcare provider.
  • Store at ambient temperature: keep below 25°C in original container, protect from moisture and light.

Avoid Interactions

Drug interactions can modify efficacy or increase risk of adverse events.

Major Interactions (Avoid)

  • Insulin or sulfonylureas: heightened risk of severe hypoglycaemia.
  • Iodinated contrast agents: may precipitate renal dysfunction, increase metformin accumulation.
  • Cimetidine: can raise sitagliptin plasma levels.

Moderate Interactions (Monitor Closely)

  • Diuretics: may affect renal clearance of metformin.
  • Beta‑blockers: can mask hypoglycaemia symptoms.
  • ACE inhibitors/ARBs: monitor renal function when combined.

Frequently Asked Questions

Mifomet is prescribed for the treatment of type 2 diabetes mellitus in adults. It combines metformin, which improves insulin sensitivity, with sitagliptin, which enhances insulin secretion, to help achieve better blood‑glucose control when diet, exercise, or single‑agent therapy are insufficient.

Metformin lowers glucose production by the liver and increases peripheral insulin sensitivity. Sitagliptin inhibits the enzyme DPP‑4, raising levels of incretin hormones that stimulate insulin release only when blood glucose is high. The dual action addresses both insulin resistance and inadequate insulin secretion.

The dosage of Mifomet is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. The prescriber will select the appropriate strength and dosing schedule according to current treatment guidelines.

Safety of Mifomet in pregnancy or lactation has not been fully established. Healthcare providers should evaluate the potential benefits against possible risks and discuss alternative treatment options with the patient before initiating therapy in these populations.

To place an order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mifomet offers a fixed‑dose combination of metformin and sitagliptin, providing both insulin‑sensitising and incretin‑enhancing effects in a single tablet. This can simplify regimens compared with taking two separate agents and may improve adherence versus more complex insulin‑based therapies.

Mifomet tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, heat and direct sunlight to maintain product stability throughout its shelf life.

Mifomet is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet is swallowed whole with a full glass of water. The exact timing and frequency are prescribed by the treating physician.

The most serious risks include lactic acidosis, a rare but potentially fatal metabolic complication, and severe hypoglycaemia when combined with insulin or sulfonylureas. Patients should be educated to recognize early symptoms and seek immediate medical attention if they occur.

Mifomet should be avoided in patients with severe renal impairment, known hypersensitivity to metformin or sitagliptin, or a history of lactic acidosis. It is also contraindicated in individuals with certain hepatic conditions or those taking medications that significantly increase the risk of adverse reactions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT